Balancing efficacy and adverse reactions using everolimus in a patient with metastatic malignant insulinoma: Case report
Int. Journal of Clinical Pharmacology and Therapeutics · 01.06.2024 · 62 (06) · 278-283
DOI: 10.5414/cp204503 ↗Kurz gefasst
Fallbericht in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, erschienen am 01.06.2024. Verfasst von Siham Rouf und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Everolimus, Insulinoma, Pancreatic Neoplasms, Hypoglycemia. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Rouf, S., Boujtat, K., El Harroudi, T., & Latrech, H. (2024). Balancing efficacy and adverse reactions using everolimus in a patient with metastatic malignant insulinoma: Case report. Int. Journal of Clinical Pharmacology and Therapeutics, 62(06), 278-283. https://doi.org/10.5414/cp204503
Vancouver
Rouf S, Boujtat K, El Harroudi T, Latrech H. Balancing efficacy and adverse reactions using everolimus in a patient with metastatic malignant insulinoma: Case report. Int. Journal of Clinical Pharmacology and Therapeutics. 2024;62(06):278-283. doi:10.5414/cp204503
BibTeX
@article{Rouf2024,
author = {Rouf, Siham and Boujtat, Khadija and El Harroudi, Tijani and Latrech, Hanane},
title = {Balancing efficacy and adverse reactions using everolimus in a patient with metastatic malignant insulinoma: Case report},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2024},
volume = {62},
number = {06},
pages = {278--283},
doi = {10.5414/cp204503}
}
EUVIMED